Chiasma completes Phase I clinical study of Octreolin successfully Chiasma, Inc., a privately held biopharma company, announced that it offers successfully completed a Stage I clinical study evaluating the security and pharmacokinetics of its proprietary item Octreolin, which contains the active ingredient octreotide actetate and is definitely administered orally journal de la pharmacie . Octreolin demonstrated a PK profile similar to that of subcutaneously injected octreotide acetate. The Company also announced that it was advancing towards its goal of beginning a pivotal trial by the finish of the entire year for Octreolin in acromegaly, a hormonal disorder that outcomes from an excessive amount of growth hormones . Chiasma offers submitted an Orphan Drug program to the US FDA for acromegaly and can submit an application for Orphan Medicinal Item Designation to the European Company for the Evaluation of Medicinal Items shortly.
Chicago forces city employees to participate in ‘wellness’ plan or pay even more for health insurance In order to cut in half the $500 million-a-year healthcare bill precipitated by Chicago’s city employees, Mayor Rahm Emanuel has initiated a fresh public employee wellness plan that he hopes will change things around. But according to the Chicago Sun-Times, the program is mandatory for nearly all of the city’s unions and its members, including actually those members that currently abide by their own personal wellness programs – – and individuals that do not adhere to it will be subjected to added fees on the health insurance premiums.